摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[3-(2-Methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5-one

中文名称
——
中文别名
——
英文名称
1-[3-(2-Methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5-one
英文别名
——
1-[3-(2-Methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5-one化学式
CAS
——
化学式
C21H22N4O2
mdl
——
分子量
362.4
InChiKey
AGUBHJHPFPDNQT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    58
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
    申请人:SANOFI-SYNTHELABO
    公开号:EP1184385A1
    公开(公告)日:2002-03-06
    The invention relates to a dihydroimidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: wherein : X represents hydrogen atoms, a sulphur atom or an oxygen atom; Y represents a bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted; when Y represents a bond, a methylene group optionally substituted or a carbonyl group, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a naphthyl group, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents; when Y represents an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a naphthyl group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β.
    该发明涉及一种由化学式(I)表示的二氢咪唑并[1,2-a]嘧啶酮衍生物或其盐:其中:X代表氢原子、原子或氧原子;Y代表键、氧原子、原子、磺酰基、磺氧基、羰基、氮原子(可选择性取代)或取代的亚甲基基团;R1代表可选择性取代的2、3或4-吡啶基团;当Y代表键、可选择性取代的亚甲基基团或羰基时,R2代表C1-6烷基基团、C3-6环烷基基团、C1-2全氟烷基基团、C1-3卤代烷基基团、C1-4烷基团、C1-4烷氧基团、基团、苯基团、苄基团、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环;苄基团、苯基、或环可选择性地被1至3个取代基取代;当Y代表氧原子、原子、磺酰基、磺氧基或氮原子(可选择性取代)时,R2代表C1-6烷基基团、C3-6环烷基基团、C1-2全氟烷基基团、C1-3卤代烷基基团、基团、苄基团、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环;苄基团、苯基、或环可选择性地被1至3个取代基取代;n代表0至3。该发明还涉及一种药物,其包括所述衍生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病。
  • 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives
    申请人:——
    公开号:US20040087598A1
    公开(公告)日:2004-05-06
    The invention relates to pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represent a 2,3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represent a C 1-16 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3&bgr; such as Alzheimer's disease.
    本发明涉及一种以式(I)表示的嘧啶酮衍生物或其盐,其中X代表氢原子、原子、氧原子或C1-2烷基和氢原子;Y代表键,乙烯基乙炔基,1,2-环丙烷基,氧原子,原子,磺酰基,磺酸氧化物基,羰基,氮原子(可选择性取代)或取代的亚甲基基团;R1代表2,3或4-吡啶基团,可选择性取代为C3-6环烷基,C1-4烷基,C1-4烷氧基,苄基或卤原子;当Y代表键,可选择性取代的亚甲基基团或羰基时,则R2代表C1-16烷基,C3-6环烷基,C1-4烷基,C1-4烷氧基,C1-2全氟烷基,C1-3卤代烷基,5,6,7,8-四氢基环,基环,苯基,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环;当Y代表乙烯基乙炔基,氧原子,原子,磺酰基,磺酸氧化物基或可选择性取代的氮原子时,则R2代表C1-6烷基,C3-6环烷基,C1-2全氟烷基,C1-3卤代烷基,基环,5,6,7,8-四氢基环,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环。本发明还涉及一种药物,其包含所述衍生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,例如阿尔茨海默病。
  • 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives
    申请人:Almario Garcia Antonio
    公开号:US20060014762A1
    公开(公告)日:2006-01-19
    The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.
    本发明涉及一种由式(I)或其盐所表示的嘧啶酮衍生物:其中:X代表氢原子,原子,氧原子或C1-2烷基和氢原子;Y代表键,乙烯基乙炔基,1,2-环丙基,氧原子,原子,磺酰基,磺酸氧基,羰基,氮原子(可选地被取代)或取代的亚甲基基团;R1代表2、3或4-吡啶基团,可选地被C3-6环烷基,C1-4烷基,C1-4烷氧基,苄基或卤原子取代;当Y代表键,可选地被取代的亚甲基基团或羰基时,R2代表C1-6烷基,C3-6环烷基,C1-4烷基,C1-4烷氧基,C1-2全卤代烷基,C1-3卤代烷基,5,6,7,8-四氢基环,基环,苯基基,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环;当Y代表乙烯基乙炔基,氧原子,原子,磺酰基,磺酸氧基或可选地被取代的氮原子时,R2代表C1-6烷基,C3-6环烷基,C1-2全卤代烷基,C1-3卤代烷基,基环,5,6,7,8-四氢基环,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环。本发明还涉及一种药物,其包含所述衍生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,如阿尔茨海默病。
  • 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES
    申请人:ALMARIO GARCIA Antonio
    公开号:US20080027078A1
    公开(公告)日:2008-01-31
    The invention relates to therapeutic uses of a pyrimidone derivative represented by formula (I) or a salt thereof: Wherein X, Y, R1, R2, m and n are as defined herein. Specifically, a medicament comprising the said derivative or a salt thereof as an active ingredient is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.
    本发明涉及一种嘧啶酮衍生物或其盐的治疗用途,其化学式为(I),其中X、Y、R1、R2、m和n如本文所定义。具体而言,该衍生物或其盐作为活性成分的药物可用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,例如阿尔茨海默病。
  • 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES
    申请人:SANOFI-SYNTHELABO
    公开号:EP1315731B1
    公开(公告)日:2004-06-16
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯